Refractory Distal Colitis

Challenges in Inflammatory Bowel Disease: Second Edition

Volumn , Issue , 2008, Pages 124-143

  Travis, Simon ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Bleeding; Diagnosis; Fatty acids; Pathophysiology; Refractory distal colitis

Indexed keywords

EID: 79958830248     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470753170.ch10     Document Type: Chapter

References (122)

1. Irvine EJ. Assessing outcome in randomized clinical trials: inflammatory bowel disease.In: Satsangi J, Sutherland LR, eds.Inflammatory Bowel Diseases. London: Churchill Livingstone; 2003:319-33.
2. Jarnerot G, Lennard-Jones JE, Bianchi-Porro G, et al. Medical treatment of refractory distal ulcerative colitis. Gastroenterol Int 1991;4:93-8.
3. Griffin MG, Miner PB. Refractory distal colitis-explanations and options. Aliment Pharmacol Ther 1996;10:39-48.
4. Travis SPL, Dannatt E, McGovern DPB, Beale A, Jagadeesan S. Managed care for distal ulcerative colitis. Gut 2001;48(suppl 2):A87.
5. Amasheh S, Barmeyer C, Koch CS, et al. Cytokine-dependent transcriptional down-regulation of epithelial sodium channels in ulcerative colitis. Gastroenterology 2004;126:1711-20.
6. Ortega-Cava CF, Ishihara S, Rumi MA, et al. Strategic compartmentalization of toll-like receptor 4 in the mouse gut. J Immunol 2003;170:3977-85.
7. Tanaka M, Saito H, Kusumi T, et al. Spatial distribution and histogenesis of colorectal paneth cell metaplasia in idiopathic inflammatory bowel disease. J Gastroenterol Hepatol 2001;16:1353-9.
8. Sangfelt P, Carlson M, Thorn M, et al. Local release of human neutrophil lipocalin (HNL), IL-8 and TNF alpha is decreased as response to topical prednisolone treatment in distal ulcerative colitis and proctitis. Dig Dis Sci 2002;47:2064-9.
9. Medina C, Videla S, Radomski A, et al. Increased activity and expression of matrix metalloproteinase-9 ina rat model of distal colitis. Am J Physiol 2003;284: G116-22.
10. Velazquez OC, Lederer HM, Rombeau JL. Butyrate and the colonocyte. Production, absorption, metabolism, and therapeutic implications. Adv Exp Med Biol 1997;427:123-34.
11. Menzel T, Luhrs H, Zirlik S, et al. Butyrate inhibits leucocyte adhesion to endothelial cells via modulation of VCAM-1. Inflamm Bowel Dis 2004;10:122-8.
12. McLaren WJ, Anikijenko P, Thomas SG, et al. In vivo detection of morphological and microvascular changes of the colon in association with colitis using fiberoptic confocal imaging (FOCI). Dig Dis Sci 2002;47:2424-33.
13. Beyak MJ, Ramji N, Krol KM, et al. Two TTX-resistant sodium currents in mouse colonic dorsal root ganglia neurones and their role in colitis induced hyperexcitability. Am J Physiol 2004;287: G845-55.
14. Linden DR, Sharkey KA, Mawe GM. Enhanced excitability of myenteric AH neurones in the inflamed guinea-pig distal colon. J Physiol 2003;547(Pt 2): 589-601.
15. Mahida YR, Rolfe V. Host-bacterial interactions in inflammatory bowel disease. Clin Sci 2004;107: 331-41.
16. Ayres RC, Gillen CD, Walmsley RS, Allan RN. Progression of ulcerative proctosigmoiditis: incidence and factors influencing progression. Eur J Gastroenterol & Hepatol 1996;8:555-8.
17. Moum B, Ekbom A, Vatn MH, Elgjo K. Change in the extent of colonoscopic and histological involvement in ulcerative colitis over time Am J Gastrenterol 1999;94:1564-9.
18. Hamilton M, Dick R, Crawford L, et al. Is the proximal demarcation of ulcerative colitis determined by the territory of the inferior mesenteric artery? Lancet 1995;345:688-90.
19. Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. Science 2004;305:626-9.
20. Jenkins D, Goodall A, Scott BB. Ulcerative colitis: one disease or two (quantitative histological differences between distal and extensive disease). Gut 1990;31: 426-30.
21. King TM, Biddle WL, Bhatia P, Moore J, Miner PB. Colonic mucosal mast cell distribution at the line of demarcation of active ulcerative colitis. Dig Dis Sci 1992;37:490-5.
22. Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003;114: 39-43.
23. Shale MJ, Riley SA. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003;18:191-8.
24. Kane SV, Cohen RD, Aikens JE, Hanauer SB. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 2001;96:2929-33.
25. Cuffari C, Hunt S, Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 2001;48:642-8.
26. Frieri G, Giacomelli R, Pimpo M, et al. Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis. Gut 2000;47: 410-6.
27. Christensen LA, Fallingborg J, Jacobsen BA, et al. Comparative bioavailability of 5-aminosalicylic acid from controlled release preparation and an azo-bond preparation. Aliment Pharmacol Ther 1994;8: 289-94.
28. Naganuma M, Iwao Y, Ogata H, et al. Measurement of colonic mucosal concentrations of 5-aminosalicylic acid is useful for estimating its therapeutic efficacy in distal ulcerative colitis: comparison of orally administered mesalamine and sulfasalazine. Inflamm Bowel Dis 2001;7:221-5.
29. Hussain FN, Ajjan RA, Kapur K, Moustafa M, Riley SA. Once versus divided daily dosing with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters. Aliment Pharmacol Ther 2001;15:53-62.
30. Hussain FN, Ajjan RA, Riley SA. Dose loading with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters. Br J Clin Pharmacol 2000;49: 323-30.
31. Frieri G, Mariateresa P, Brigida G, et al. Long-term oral plus topical mesalazine in frequently relapsing ulcerative colitis. Dig Liver Dis 2005;37:92-96.
32. Williams CN, Haber G, Aquino JA. Double-blind, placebo-controlled evaluation of 5-ASA suppositories in active distal proctitis and measurement of extent of spread using 99mTc-labelled 5-ASA suppositories. Dis Sci 1987;32:71S-5S.
33. Brown J, Haines S, Wilding IR. Colonic spread of three rectally administered mesalazine (Pentasa) dosage forms in healthy volunteers as assessed by gamma scintigraphy. Aliment Pharmacol Ther 1997;11:685-91.
34. Van Bodegraven AA, Boer RO, Lourens J, Tuynman HARE, Sindram JW. Distribution of mesalazine enemas in active and quiescent ulcerative colitis. Aliment Pharmacol Ther 1996;10:327-32.
35. Arlander E, Cederlund T, Mare K. No volume effect on retrograde colonic spread of rectally-administered ropivacaine gel. Aliment Pharmacol Ther 2003;15: 655-60.
36. Honda M, Orii F, Ayabe T, et al. Expression of glucocorticoid receptor β in lymphocytes of patients with glucocorticoid-resistant ulcerative colitis. Gastroenterology 2000;118:819-66.
37. Hearing SD, Norman M, Probert CSJ, et al. Predicting therapeutic outcome in severe ulcerative colitis by measuring in vitro steroid sensitivity of proliferating peripheral blood lymphocytes. Gut 1999;45:382-8.
38. Sutherland L, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2003;3:CD000543.
39. Marshall JK, Irvine EJ. Rectal corticosteroids versus alternative treatment in ulcerative colitis: a meta-analysis. Gut 1997;40:775-81.
40. Truelove SC, Witts LJ. Cortisone in ulcerative colitis: a final report on a therapeutic trial. Br Med J 1955;2: 1041-8.
41. Edwards FC, Truelove SC. The course and prognosis of ulcerative colitis. Part I: short-term prognosis. Part II: long-term prognosis. Gut 1963;4:299-315.
42. Sninsky CA, Cort DH, Shanahan F, et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis: a multicentre study. Ann Intern Med 1990;115:350-5.
43. Sandborn WJ, Hanauer SB, Katz S, et al. Efficacy and safety of Asacol 4.8 g/day (800 mg tablet) compared to 2.4 g/day (400 mg tablet) in treating moderately active ulcerative colitis Am J Gastroenterol 2005;100:2478-85.
44. Truelove SC, Watkinson G, Draper G. Comparison of corticosteroid and SASP therapy in ulcerative colitis. Br Med J 1962;2:1708-11.
45. Lennard-Jones JE, Longmore AJ, Newell AC, Wilson CWE, Avery Jones F. An assessment of prednisone, Salazopyrin and topical hydrocortisone hemisuccinate used as outpatient treatment for ulcerative colitis. Gut 1960;1:217-22.
46. Baron JH, Connell AM, Kanaghinis TG, et al. Outpatient treatment of ulcerative colitis: comparison between three doses of oral prednisone. Br Med J 1962;2:441-3.
47. Cameron EA, Binnie JA, Balan K, et al. Oral prednisolone metasulphobenzoate in the treatment of active ulcerative colitis. Scand J Gastroenterol 2003;38:535-7.
48. Gionchetti P, Rissole F, Ventura A, et al. Comparison of mesalazine suppositories in proctitis and distal proctosigmoiditis. Aliment Pharmacol Ther 1997;11: 1053-7.
49. Jenkins D, Balsitis M, Gallivan S, et al. Guidelines for the initial biopsy diagnosis of suspected chronic idiopathic inflammatory bowel disease. BSG Guidelines in Gastroenterology, BSG London 1997, or website http://www.bsg.org.uk/clinical/data/gmpcd.htm.
50. Loftus EV, Kane SV, Bjorkman D. Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2004;19:179-89.
51. Marshall JK, Irvine EJ. Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis. Aliment Pharmacol Ther 1995;9:293-300.
52. Lee FI, Jewell DP, Mani V, et al. A randomised trial comparing mesalazine and prednisolone foam enemas in patients with acute distal ulcerative colitis. Gut 1996;38:229-33.
53. Marteau P, Probert C, Lindgren S, et al. Comparison of the efficacy and tolerability of oral 4 g Pentasa (mesalazine) for 8 weeks combined during the initial 4 weeks with either Pentasa 1 g/100 mL enema or placebo enema in extensive mild/moderate active colitis: a randomised, parallel, double-blind trial. Gut 2005;54:960-5.
54. Safdi M, DeMicco M, Sninsky C, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 1997;92:1867-71.
55. Richter F, Scheppach W. Innovations in topical therapy. Bailliere's Clin Gastroenterol 1997;11: 97-109.
56. Lemann M, Galian A, Rutgeerts P, et al. Comparison of budesonide and 5-aminosalicylic acid enemas in active distal ulcerative colitis. Aliment Pharmacol Ther 1995;9:557-62.
57. Hanauer SB, Robinson M, Pruitt R, et al. Budesonide enema for the treatment of active distal ulcerative colitis and proctitis: a dose-ranging study. Gastroenterology 1998;115:525-32.
58. Mulder CJJ, Fockens P, Meijer JWR, et al. Beclomethasone dipropionate (3mg) versus 5-aminosalicylic acid (2 g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis. Eur J Gastroenterol Hepatol 1996;8:549-53.
59. Campieri M, Gionchetti P, Belluzzi A, et al. Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis. Gut 1991;32:929-31.
60. Campieri M, Paoluzi P, D'Albaiso G, et al. Better quality of therapy with 5-ASA colonic foam in active ulcerative colitis: a multicenter comparative trial with 5-ASA enemas. Dig Dis Sci 1993;38: 1843-50.
61. Biddle WL, Miner PB. Long-term use of mesalamine enemas to induce remission in ulcerative colitis. Gastroenterol 1990;99:113-8.
62. Vernia P, Annese V, Bresci G, et al. Topical butyrate improves efficacy of 5-ASA in refractory distal ulcerative colitis: results of a multicentre trial. Eur J Clin Invest 2003;33:244-8.
63. Rao SSC, Read NW, Brown C, Bruce C, Holdsworth CD. Studies on the mechanism of bowel disturbance in ulcerative colitis. Gastroenterology 1987;93:934-40.
64. Hebden JM, Blackshaw PE, Perkins AC, Wilson CG, Spiller RC. Limited exposure of the distal colon to orally-dosed formulation is further exaggerated in active left-sided ulcerative colitis. Aliment Pharmacol Ther 2000;14:155-61.
65. Travis SPL, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut 1996;38:905-10.
66. Jarnerot G, Rolny P, Sandberg-Gertzen H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology 1985;89:1005-13.
67. Hawthorne AB. Ciclosporin and refractory colitis. Eur J Gastroenterol Hepatol 2003;15:239-44.
68. Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 1994;107:3-11.
69. Meucci G, Vecchi M, Astegiano M, et al. The natural history of ulcerative proctitis: a multicenter, retrospective study. Am J Gastroenterol 2000;95:469-73.
70. D'Haens G, Gebboes K, Peeters M, et al. Patchy caecal inflammation associated with distal ulcerative colitis: a prospective endoscopic study. Am J Gastroenterol 1997;92:1275-9.
71. Lennard-Jones JE, Misiewicz JJ, Connell AM, et al. Prednisolone as maintenance treatment for ulcerative colitis in remission. Lancet 1965;1:188-9.
72. Sutherland L, Roth D, Beck P, May G, Makiyama K. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2002;4:CD000544.
73. Travis SPL, Tysk C, de Silva HJ, et al. Optimum dose of olsalazine for maintaining remission in ulcerative colitis. Gut 1994;35:1282-6.
74. Courtney M, Nunes D, Bergin C, et al. Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis. Lancet 1992;339:1279-81.
75. Green JRB, Gibson JA, Kerr GD, et al. Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months: ABACUS investigator group. Aliment Pharmacol Ther 1998;12:1207-16.
76. Hanauer SB. Caution in the interpretation of safety and efficacy differences in clinical trials comparing aminosalicylates for ulcerative colitis. Am J Gastroenterol 2003;98:215-6.
77. Marteau P, Crand J, Foucault M, Rambaud J-C. Use of mesalazine slow-release suppositories 1g three times per weeks to maintain remission of ulcerative proctitis: a randomised double blind placebo controlled multicentre study. Gut 1998,42: 195-9.
78. McGovern DPB, Travis SPL. Thiopurine therapy: when to start and when to stop. Eur J Gastroenterol Hepatol 2003;15:219-24.
79. Falasco G, Zinicola R, Forbes A. Review article: immunosuppressants in distal ulcerative colitis. Aliment Pharmacol Ther 2002;16:181-7.
80. Hawthorne AB, Logan RFA, Hawkey CJ, et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. Br Med J 1992;305:20-2.
81. Lemann M, Bouhnik Y, Colombel J, et al. Randomized, double-blind, placebo-controlled, multicentre, azathioprine withdrawal trial in Crohn's disease. Gastroenterology 2002;122:A23.
82. Oren R, Arber N, Odes S, et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology 1996;110:1416-21.
83. Cummings JRF, Gorard DA, McIntyre AS, Travis SPL, Jewell DP. Oral methotrexate in ulcerative colitis. Aliment Pharmacol Ther 2005;21:385-9.
84. Bjorck S, Dahlstrom A, Ahlman H. Treatment of distal colitis with local anaesthetic agents. Pharmacol Toxicol 2002;90:173-80.
85. Saibil FG. Lidocaine enemas for intractable distal ulcerative colitis: efficacy and safety [Abstract]. Gastroenterology 1998;114:A1073.
86. Arlander E, Ost A, Stahlberg D, Lofberg R. Ropivacaine gel in active distal ulcerative colitis and proctitis-a pharmacokinetic and exploratory clinical study. Aliment Pharmacol Ther 1996;10: 73-81.
87. Hillingso JG, Kjeldsen J, Scmidt PT, et al. Effects of topical ropivacaine on eicosanoids and neurotransmitters in the rectum of patients with distal colitis. Scand J Gastroenterol 2002;37: 325-9.
88. Forbes A, Britton TC, House IM, et al. Safety and efficacy of acetarsol suppositories in unresponsive proctitis. Aliment Pharmacol Ther 1989;3:553-6.
89. Pullan RD, Ganesh S, Mani V, et al. Comparison of bismuth citrate and 5-aminosalicylic acid enemas in active distal ulcerative colitis: a controlled trial. Gut 1993;34:676-9.
90. Khan Z, Macdonald C, Wicks AC, et al. Use of the 'nutriceutical' bovine colostrum for the treatment of distal colitis: results from an initial study. Aliment Pharmacol Ther 2002;16:1917-22.
91. Sandborn WJ, Tremaine WJ, Schroeder KW, et al. A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis. Gastroenterology 1994;106:1429-35.
92. Sinha A, Nightingale JMD, West KP, Berlanga-Acosta J, Playford RJ. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N Engl J Med 2003;349:350-7.
93. Kono T, Nomura M, Kasai S, Kogho Y. Effect of ecabet sodium enema on mildly to moderately active ulcerative proctosigmoiditis: an open-label study. Am J Gastroenterol 2001;96:793-7.
94. Jarlov AE, Munkholm P, Schmidt PN, et al. Treatment of active distal ulcerative colitis with immunoglobulin G enemas. Aliment Pharmacol Ther 1993;7:561-5.
95. Schreiber S, Heinig T, Thiele HG, Raedler A. Immunoregulatory role of interleukin-10 in patients with inflammatory bowel disease. Gastroenterology 1995;108:1434-44.
96. Pullan RD, Rhodes J, Ganesh S, et al. Transdermal nicotine for active ulcerative colitis. N Engl J Med 1994;330:811-95.
97. Thomas GAO, Rhodes J, Mani V, et al. Transdermal nicotine as maintenance therapy for ulcerative colitis. N Engl J Med 1995;332:988-92.
98. Thomas GAO, Rhodes J, Ragunath K, et al. Transdermal nicotine compared with oral prednisolone therapy for active ulcerative colitis. Eur J Gastroenterol Hepatol 1996;8:769-76.
99. Sandborn WJ, Tremaine W, Offord KP, et al. A randomized, double-blind, placebo controlled trial of transdermal nicotine for mildly to moderately active ulcerative colitis. Ann Intern Med 1997;126:364-71.
100. Guslandi M, Frego R, Vitale E, Testoni PA. Distal ulcerative colitis refractory to rectal mesalamine: role of transdermal nicotine versus oral mesalamine. Can J Gastroenterol 2002;16:293-6.
101. Sandborn WJ, Tremaine WJ, Leighton JAS, et al. Nicotine tartrate liquid enemas for mildly to moderately active left-sided ulcerative colitis unresponsive to first-line therapy: a pilot study. Aliment Pharmacol Ther 1997;11:663-71.
102. Green JT, Thomas GAO, Rhodes J, et al. Nicotine enemas for active ulcerative colitis-a pilot study. Aliment Pharmacol Ther 1997;11:859-63.
103. Gasbarrini G, Mingrone G, Giancaterini A, et al. Effects of propionyl-L-carnitine topical irrigation in distal ulcerative colitis: a preliminary report. Hepatogastroenterolgy 2003;50:1385-9.
104. Senagore AJ, MacKeigan JM, Scheider M, Ebrom JS. Short-chain fatty acid enemas: a cost-effective alternative in the treatment of non-specific proctosigmoiditis. Dis Colon Rectum 1992;35:923-7.
105. Vernia P, Marcheggiano A, Caprilli R, et al. Short-chain fatty acid topical treatment in distal ulcerative colitis. Aliment Pharmacol Ther 1995;9:309-13.
106. Patz J, Jacobsohn WZ, Gottschalk-Sabag S, Zeides S, Braverman DZ. Treatment of refractory distal colitis with short-chain fatty acid enemas. Am J Gastroenterol 1996;91:731-4.
107. Breuer RI, Soergel KH, Lashner BA, et al. Short-chain fatty acid rectal irrigation for left-sided ulcerative colitis: a randomized, placebo-controlled trial. Gut 1997;40:485-91.
108. Scheppach W, Group G-A. Treatment of distal ulcerative colitis with short-chain fatty acid enemas: a placebo-controlled trial. Dig Dis Sci 1996;41: 2254-9.
109. Steinhart AH, Hiruki T, Brezezinski A, Baker JP. Treatment of left-sided ulcerative colitis with butyrate enemas: a controlled trial. Aliment Pharmacol Ther 1996;10:729-36.
110. Riley SA, Gupta I, Mani V. A comparison of sucralfate and prednisolone enemas in the treatment of active distal ulcerative colitis. Scand J Gastroenterol 1989;24:1014-18.
111. Campieri M, Gionchetti P, Belluzzi A, et al. Sucralfate, 5-aminosalicylic acid and placebo enemas in the treatment of distal ulcerative colitis. Eur J Gastroenterol & Hepatol 1991;3:41-4.
112. Ardizzone S, Petrillo M, Antonacci CM, Bianchi Porro G. Sucralfate and hydrocortisone enemas in the treatment of active ulcerative proctitis-a randomised single-blind comparative study. Aliment Pharmacol Ther 1996;10:957-60.
113. Wright JP, Winter TA, Candy S, Marks IS. Sucralfate and methylprednisolone enemas in active ulcerative colitis: a prospective, single-blind study. Dig Dis Sci 1999;44:1899-901
114. van Outryve M, Huble F, van Eeghem P, et al. Comparison of Ridrogel versus prednisolone, both administered rectally, for the treatment of active ulcerative colitis [Abstract]. Gastroenterology 1996;110:A1035.
115. Auwerda JJ, Zijlstra FJ, Tak CJ, et al. Ridogrel enemas in distal ulcerative colitis. Eur J Gastroenterol Hepatol 2001;13:397-400.
116. Ben-Ayre E, Goldi E, Wengrower D, et al. Wheat grass juice in the treatment of active distal ulcerative colitis: a randomised double-blind placebo controlled trial. Scand J Gastroenterol 2002;37: 444-9.
117. Ohkusa T, Okayasu I, Ogihara T, et al. Induction of experimental ulcerative colitis by Fusobacterium varium isolated from colonic mucosa of patients with ulcerative colitis. Gut 2003;52:79-83.
118. Carty E, Rampton DS. Evaluation of new therapies for inflammatory bowel disease. Br J Clin Pharmacol 2003;56:351-61.
119. Radford-Smith GS, Edwards JE, Purdie DM, et al. Protective role of appendicectomy on onset and severity of ulcerative colitis and Crohn's disease. Gut 2002;51:808-13.
120. Okazaki K, Onodera H, Watanabe N, et al. A patient with improvement of ulcerative colitis after appendectomy. Gastroenterology 2000;119: 502-6.
121. Brunel M, Penne C, Tiret E, Balladur P, Parc R. Restorative proctocolectomy for distal ulcerative colitis. Gut 1999;45:542-5.
122. D'Albasio G, Pacini F, Camarri E, et al. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. Am J Gastroenterol 1997;92:1143-7.